ALQA - Alliqua BioMedical, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
+0.2467 (+10.11%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close2.4400
Bid0.0000 x 2200
Ask0.0000 x 900
Day's Range2.3787 - 2.8500
52 Week Range1.5500 - 5.2400
Avg. Volume83,680
Market Cap2.241M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.80
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical

    Adynxx, Inc., (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced May 29, 2019 as payment date for the special cash dividend announced by Alliqua Biomedical, Inc. (formerly Nasdaq:ALQA) on April 11, 2019.  The special cash dividend entitled each share of Alliqua common stock outstanding as of the close of business on April 22, 2019 to receive $1.05 in cash, subject to the consummation of Alliqua’s previously announced merger transaction with Adynxx. The merger was consummated on May 3, 2019, immediately prior to which Alliqua effected a six-for-one reverse stock split.

  • GlobeNewswire2 months ago

    Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors

    Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced the completion of its merger with Alliqua BioMedical, Inc.

  • GlobeNewswire3 months ago

    Alliqua BioMedical CEO Provides Update to Shareholders

    Great progress has been made with this exciting company, including receipt of a substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, the company’s lead product intended to both reduce postoperative pain and the need for opioid-based therapies. First, TOP intends to use the 20,000 patient records they developed over the past 10 years with Tikun Olam Israel, to identify the most appropriate assets to take through an FDA process with a proprietary extract, Avidekel. As a shareholder of Alliqua Biomedical, you will own shares in both of these exciting companies.

  • GlobeNewswire3 months ago

    Alliqua BioMedical Declares Contingent Special Dividend of $1.05 per Share and Announces Record Date for the Contingent Special Dividend and the Spin-Off of Contract Manufacturing Business

    The payment of the Special Dividend is subject to the consummation of Alliqua’s previously announced merger transaction with Adynxx, Inc. (the “Adynxx Merger”), a privately held biopharmaceutical company (the “Special Dividend Condition”).  In addition, the Distribution is subject to the satisfaction of all conditions to closing of the previously announced merger transaction (the “TOP Merger”) between AquaMed and TO Pharmaceuticals, LLC (“TOP”) and the substantially simultaneous consummation of the TOP Merger (the “Distribution Condition”). It is currently expected that the payment date for the Special Dividend and the distribution date for the Distribution will be as soon as practicable after satisfaction of the Special Dividend Condition and the Distribution Condition, as applicable, and in each case, no later than June 21, 2019.

  • GlobeNewswire7 months ago

    Alliqua Biomedical CEO Provides Update to Shareholders

    Based on the positive response to that news, we continue to be encouraged about the potential these transactions have to create longer-term value for our shareholders. This transaction allowed Alliqua to strengthen our balance sheet and focus on maximizing the value of our remaining assets. In early 2018, we retained HC Wainwright to run an extensive process to determine the best way to maximize the value of our remaining assets for the benefit of our shareholders.

  • GlobeNewswire7 months ago

    New Research: Key Drivers of Growth for Zillow Group, Woodward, Navistar International, Multi-Color, Ferrellgas Partners, and Alliqua BioMedical — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE7 months ago

    What to Watch as Healthcare Stocks Continue to Outperform the Market

    Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally. Earlier this month, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) also recently announced that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy.

  • Benzinga8 months ago

    Trade The Market, Not Your Expectations

    True to form, November has proven to be just as lucrative as in previous years. I’m currently in the midst of another winning streak after finishing up my twelfth green day in a row, my sixteenth for the ...

  • ACCESSWIRE8 months ago

    Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma

    CORAL GABLES, FL / ACCESSWIRE / November 29, 2018 / The healthcare industry is evolving but isn't without its hurdles. While doctors and researchers work to find cures and solutions to both common and ...

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Alliqua BioMedical and Catalyst Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Shares of Alliqua BioMedical more than doubled on Wednesday on news of a cannabis relatedspin off. Shares of Catalyst Pharmaceuticals also saw big gains on an FDA approval of its rare autoimmune drug, Firdapse. Alliqua BioMedical, Inc. shares closed up 63.19% on Wednesday on skyrocket trading volume compared to usual.

  • Benzinga8 months ago

    Cannabis Connection Sends Alliqua Shares Soaring Nearly 200%

    Shares of  Alliqua Biomedical Inc (NASDAQ: ALQA ), a company that has unwound itself in phases, were more than doubling in value Wednesday. The stock was trading higher by more than 100 percent at $3.33 ...

  • ACCESSWIRE8 months ago

    Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix

    CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.

  • GlobeNewswire8 months ago

    Alliqua BioMedical to spin off and merge its Contract Manufacturing Business with TO Pharmaceuticals LLC to Create an Independent, Publicly Traded Company focused on Cannabinoid-Based Pharmaceutical Therapies

    Alliqua BioMedical, Inc. (ALQA) and TO Pharmaceuticals LLC, a privately held cannabinoid-based pharmaceutical therapy company (“TOP”), today announced plans for Alliqua to spin off its AquaMed Technologies, Inc. (“AquaMed”) subsidiary, which develops, manufactures and markets high water content, electron beam cross-linked aqueous polymer sheet hydrogel products and merge it with TOP, creating a new public bio-pharmaceutical company to be called TO Pharma, focused on discovering, developing and commercializing novel therapeutics based on TOP’s proprietary cannabinoid product platform in a number of FDA-regulated clinical indications and in select OTC markets. Upon consummation of the spin off and merger, Alliqua’s former shareholders will retain a minority stake with the former members of TOP holding a majority interest in TO Pharma.  In connection with this transaction, TO Pharma intends to apply to list its shares of common stock on the Nasdaq Stock Market.

  • Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners
    American City Business Journals9 months ago

    Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners

    A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.

  • PR Newswire9 months ago

    Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation

    LANGHORNE, Pa. and SAN FRANCISCO, Oct. 12, 2018 /PRNewswire/ -- Alliqua BioMedical, Inc. (ALQA) and Adynxx, Inc., a privately held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis. The proposed merger will create a public clinical-stage pharmaceutical company focused on developing a platform of first-in-class, disease-modifying, non-opioid therapies for the treatment of pain.  Adynxx's lead product candidate, brivoligide for the reduction of postoperative pain, is intended to provide long-term pain relief and reduced opioid usage with a single administration at the time of surgery in a group of patients with a greater risk of experiencing increased and prolonged pain following surgery.

  • How Does Investing In Alliqua BioMedical Inc (NASDAQ:ALQA) Impact Your Portfolio?
    Simply Wall St.10 months ago

    How Does Investing In Alliqua BioMedical Inc (NASDAQ:ALQA) Impact Your Portfolio?

    Anyone researching Alliqua BioMedical Inc (NASDAQ:ALQA) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...